Interesting ImagesImmunoscintigraphy With 99mTc-Nimotuzumab for Planning Immunotherapy in Patients With Bone Metastases Due to Prostate CancerQuián, Yamilé P. MD, PhD; Crombet, Tania MD, PhD; Batista, Juan F. MD; Prats, Anaís MSc; Perera, Alejandro PhD Author Information From the *Direction for Clinical Research, Isotope Center, Havana, Cuba; and †Center of Molecular Immunology, Havana, Cuba. Received for publication August 1, 2015; revision accepted August 18, 2015. Conflicts of interest and sources of funding: none declared. Correspondence to: Yamile Peña Quián, MD, PhD, Direction for Clinical Research, Isotope Center, 34 St. 4501 e/ 34 y 45, Kohly, Playa, PO Box 11300, Havana, Cuba. E-mail: [email protected]; [email protected]. Clinical Nuclear Medicine: March 2016 - Volume 41 - Issue 3 - p 244-246 doi: 10.1097/RLU.0000000000001011 Buy Metrics Abstract Detection of bone metastases indicates poor prognosis for patients with prostate cancer. The immunotherapy with monoclonal antibody has been an important advance in the treatment of the cancer in the last years. Nimotuzumab is a humanized IgG1 monoclonal antibody directed against epidermal growth factor receptor that has been evaluated in solid tumors. The authors show images of 2 patients with bone metastases secondary to prostate cancer, “pre-cold therapy” with nimotuzumab. Immunoscintigraphic images were acquired 4 and 24 hours after the intravenous administration of 1110 MBq (30 mCi) of 99mTc-labeled nimotuzumab. Bone metastases expressing the receptor are visualized. Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.